A Study of Oral 7HP349 (Alintegimod) in Combination With Ipilimumab Followed by Nivolumab Monotherapy
7 Hills Pharma, LLC
7 Hills Pharma, LLC
KaliVir Immunotherapeutics
Centre Oscar Lambret
Dana-Farber Cancer Institute
Psyence Australia Pty Ltd
Dana-Farber Cancer Institute
Pfizer
Tizona Therapeutics, Inc
Essen Biotech
University of Nebraska
Second Life Therapeutics
Elephas
Novartis
Elephas
University of Pittsburgh
Degron Therapeutics Co.
University Health Network, Toronto
University of Aarhus
AstraZeneca
Massive Bio, Inc.
UNC Lineberger Comprehensive Cancer Center
Virginia Commonwealth University
Hadassah Medical Organization
Washington University School of Medicine
Fudan University
Sensei Biotherapeutics, Inc.
Delfi Diagnostics Inc.
Institut Claudius Regaud
Genentech, Inc.
DEKA Biosciences
Columbia University
Tempus AI
Arbeitsgemeinschaft medikamentoese Tumortherapie
Sheffield Teaching Hospitals NHS Foundation Trust
University Health Network, Toronto
Taproot Health
Henan Cancer Hospital
Dana-Farber Cancer Institute
Inhibrx Biosciences, Inc
Hospices Civils de Lyon
Fondazione Policlinico Universitario Agostino Gemelli IRCCS
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
European Organisation for Research and Treatment of Cancer - EORTC
Second Affiliated Hospital of Guangzhou Medical University
Cedars-Sinai Medical Center
N.N. Petrov National Medical Research Center of Oncology
Sanguine Biosciences
Celldex Therapeutics
AO GENERIUM
University of Nebraska